Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
ASH 2014: Highlights in multiple myeloma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 3818

Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios Dimopoulos

Prof Moreau (Centre Hospitalier Universitaire de Nantes, Nantes, France) chairs a discussion with Prof Stewart (Mayo Clinic, Scottsdale, USA), Prof Mateos (University Hospital of Salamanca, Salamanca, Spain), and Prof Dimopoulos (Univeristy of Athens, Athens, Greece) for ecancertv about the data and opinions arising from ASH 2014.

The experts discuss the potential of combination therapies in relapsed and in advanced multiple myeloma; namely, carlfizomib combined with lenalidomide and the combination of pomalidomide and low-dose dexamethasone. They also touch on the use of the monoclonal antibody (anti-CD38) in relapsed disease but also in first line in combination with VMP treatment.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation